Author Archives: Millie Nelson

Orgenesis and Johns Hopkins University to build CGT Maryland Center

Orgenesis and Johns Hopkins University will build a cell and gene therapy processing facility in Maryland, US for point of care treatment. The 7,000 square-foot POCare Center, also known as the Maryland Center for Cell Therapy Manufacturing, has been partly funded by a $5 million grant from the State of Maryland with building expected to start in Q2 2022 and the facility anticipated to be operational by Q2 2023. “Orgenesis is a pioneer of decentralized processing and production of CGTs,…

Continuous processing and CGTs: MilliporeSigma on CDMO trends for 2022

BioProcess Insider spoke virtually with MilliporeSigma’s head of Process Solutions Andrew Bulpin about his predictions for the company and the CDMO space in 2022. The life sciences services division of Merck KGaA, MilliporeSigma, has been steadily increasing its contract development manufacturing organization (CDMO) services through a string of investments and expansions. The firm invested $110 million into its gene therapy CDMO business in April 2020 by building a second facility at its site in California, adding 11 production suites and more…

Cytiva and Nucleus team on custom cell media for CGTs

The collaboration with Nucleus Biologics will provide transparent and scalable manufacture of custom cell culture media, says Cytiva. Under the terms of the deal, Cytiva and cell culture firm Nucleus Biologics have partnered to develop custom media formulation and fulfillment solutions for the cell and gene therapy (CGT) space. Cytiva customers will be able to formulate their own custom cell culture media through Xuri Media AI Guide, which is based on Nucelus’ NB-AIR platform. Additionally, clients can configure their media…

Novo Nordisk Foundation invests $343m to build stem-cell research center

Novo Nordisk Foundation will invest up to $343 million over a ten-year period to establish an international research center focused on stem cell medicine. The center is a partnership entitled reNEW between the University of Copenhagen, Denmark, Murdoch Children’s Research Institute, Australia, and Leiden University Medical Center, The Netherlands. The aim of the collaboration is to drive future stem cell-based treatments. The governing hub will be based at the Faculty of Health and Medical Sciences, University of Copenhagen and Melissa…

BioNTech and Crescendo partner to develop precision immunotherapies

The collaboration sees BioNtech combine its multimodal immunotherapy expertise with Crescendo’s Humabody VH platform to produce precision immunotherapies. Crescendo Biologics, a clinical-stage immuno-oncology company developing targeted T cell enhancing therapeutics will contribute its transgenic platform to deliver fully human heavy-chain antibody domains (Humabody VH) against targets selected by BioNTech. This includes messenger RNA (mRNA) based antibodies, as well as engineered cell therapies that have the potential to treat patients with cancer and other diseases. Humabodies are the smallest part of…

TTP and CellFiber partner to ‘revolutionize’ CGTs

TTP’s experience will enable CellFiber’s technology to provide affordable cell production with a higher yield and better product quality, says firm. TTP, a technology and product development firm based in Cambridge, UK, says its experience in designing systems for production at scale and CellFiber’s technology has the potential to revolutionize the manufacture of cell therapies. Stem cell therapy can treat various diseases, including advanced Parkinson’s disease, cancer, diabetes, and heart disease. TTP claims that producing large quantities of these cells is complex, making…

Performance Cell acquired by PE, renamed Cellipont Bioservices

San Diego CDMO Performance Cell Manufacturing has been acquired by private equity firm Great Point Partners and will operate as Cellipont Bioservices.   Performance Cell Manufacturing (PCM), a contract development and manufacturing organization (CDMO) that has manufactured cell therapies for more than fifteen years, has been acquired by Great Point Partners (GPP) for an undisclosed fee. This is the latest move in a series of CDMO investments by GPP, which includes Cytovance Biologics, MaSTherCell (later acquired by Catalent in February…

Takeda drives immuno-oncology portfolio with Adaptate buy

The acquisition will add Adaptate’s novel antibody-based delta T-cell engager platform to Takeda’s immune-oncology portfolio. Takeda is set to acquire UK firm Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for the adaptation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. In addition to gaining Adaptate’s antibody-based γδ T cell engager platform, Takeda will also obtain its preclinical candidate and discovery pipeline programs. “Adaptate’s γδ T-cell engagers are engineered to specifically activate a γδ T cell-mediated immune…

Pfizer bolsters mRNA through deals with Acuitas, Codex, and Beam

Pfizer has signaled its intention of taking mRNA beyond COVID-19 through a triad of deals announced on the first day of JP Morgan’s annual healthcare conference. Pfizer has already seen major messenger RNA (mRNA) success with BioNTech and their respective COVID-19 vaccine, BNT162b2 (Comirnaty). Now, the firm has announced its plans at JP Morgan’s healthcare conference to become an mRNA powerhouse through a triumvirate of deals. The deals, described below, see Pfizer team up with Acuitas Therapeutics, Codex DNA, and…

Lithuania’s talent pool ‘ready and waiting’ to service biopharma needs, says development agency

Biopharma companies around the world have reported concerns regarding talent shortages across the industry, but Invest Lithuania says it has a large talent pool ready and waiting. There is a general consensus among professionals that the amount of talent coming through is not reflective of the huge investment in capacity being seen across the Life Sciences industry. Companies such as Lonza, SwedenBIO, and pharma recruitment firm Lead Candidate have expressed their talent shortage concerns at different points last year. However,…